Menu
Search
|

Menu

Close
X

United Therapeutics Corp UTHR.OQ (NASDAQ Stock Exchange Global Select Market)

116.52 USD
-0.00 (-0.00%)
As of 2:29 AM IST
chart
Previous Close 116.52
Open 121.49
Volume 197,500
3m Avg Volume 154,120
Today’s High 122.37
Today’s Low 115.88
52 Week High 152.55
52 Week Low 100.64
Shares Outstanding (mil) 43.44
Market Capitalization (mil) 5,381.27
Forward P/E 14.44
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.25 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
1,246
FY17
1,725
FY16
1,599
FY15
1,466
EPS (USD)
FY18
11.974
FY17
10.955
FY16
15.167
FY15
12.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
14.44
33.59
Price to Sales (TTM)
vs sector
3.30
5.69
Price to Book (MRQ)
vs sector
3.00
5.11
Price to Cash Flow (TTM)
vs sector
12.62
23.52
Total Debt to Equity (MRQ)
vs sector
13.93
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
20.98
15.05
Return on Equity (TTM)
vs sector
21.85
16.62

EXECUTIVE LEADERSHIP

Martine Rothblatt
Chairman of the Board, Chief Executive Officer, Since 2016
Salary: $1,163,710.00
Bonus: --
Michael Benkowitz
President, Chief Operating Officer, Since 2016
Salary: $733,333.00
Bonus: --
Christopher Patusky
Lead Independent Vice Chairman of the Board, Since 2007
Salary: --
Bonus: --
James Edgemond
Chief Financial Officer, Treasurer, Since 2015
Salary: $620,833.00
Bonus: --
Paul Mahon
Executive Vice President, General Counsel, Corporate Secretary, Since 2003
Salary: $815,950.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1040 SPRING ST
SILVER SPRING   MD   20910

Phone: +1301.6089292

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

SPONSORED STORIES